Our results suggest that, in contrast to rosiglitazone, Peptide 2 does not activate PPARγ and, in conditions of HFD-induced obesity and IR, Peptide 2 does not worsen HFD-induced hepatic steatosis. The gene discussed is PPARG; the disease is Hepatic steatosis.